This study is looking at a new way to treat newly diagnosed glioblastoma (a type of brain cancer). It compares the standard treatment (radiation therapy and temozolomide) with the standard treatment plus an investigational drug called ruxolitinib. You would be randomly assigned, like a coin flip, to one of these two groups. The study aims to see if adding ruxolitinib improves how long people live (overall survival) over four years. To join, you must be 18 or older and have glioblastoma confirmed by specific medical criteria. The current recruitment status is unclear.

Study design

This is an interventional study planning to enroll 190 participants. Half will receive standard treatment, and half will receive standard treatment plus ruxolitinib, assigned randomly.

What's involved

During radiation therapy, you would take ruxolitinib and temozolomide by mouth daily for 6 weeks, along with daily radiation therapy for 6 weeks. There will be a 4-week break after radiation, followed by a "maintenance" phase.

Compensation

Not stated in the trial record.

Follow-up

The study will measure overall survival at the end of the study, which is 4 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.